| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5647122 | Journal of Allergy and Clinical Immunology | 2017 | 20 Pages |
Abstract
Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children. This, when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapy.
Keywords
CPEConsortium of Food Allergy ResearchEPITDouble-blind, placebo-controlled oral food challengeCoFARDSMBOFCSPTIQRSCDIgEFood allergyimmunotherapyepicutaneous immunotherapyoral immunotherapykUASkin prick testPeanut hypersensitivityEpicutaneousOITCrude peanut extractinterquartile rangeData Safety Monitoring BoardDesensitization
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Stacie M. MD, Scott H. MD, A. Wesley MD, Donald Y.M. MD, Robert W. MD, Peter PhD, Alice K. MS, M. Cecilia PhD, David MSc, Brian P. MD, Robbie D. MD, Christine B. MD, Wendy F. PhD, Marshall MD, Hugh A. MD, Robert A. MD,